Concord Biotech Limited (NSE:CONCORDBIO)

Market Cap	119.85B -44.2%
Revenue (ttm)	11.59B +6.4%
Net Income	3.13B -4.2%
EPS	29.69 -4.8%
Shares Out	104.62M
PE Ratio	38.59
Forward PE	29.92
Dividend	10.70 (0.92%)
Ex-Dividend Date	Sep 3, 2025

Volume	82,087
Average Volume	318,468
Open	1,145.60
Previous Close	1,145.60
Day's Range	1,138.50 - 1,168.00
52-Week Range	1,100.00 - 2,150.40
Beta	0.22
RSI	38.70
Earnings Date	Feb 11, 2026

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 1,571
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CONCORDBIO

Financial Performance

In fiscal year 2025, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.